Abstract Purpose of Review We reviewed the current data on infections associated with
rituximab use published over the last 5 years. Recent Findings New literature was available …

The current era of COVID-19 is characterized by emerging variants of concern, waning
vaccine-and natural infection-induced immunity, debate over the timing and necessity of …

Objective To assess whether rituximab (RTX) is associated with worse COVID-19 outcomes
among patients with rheumatoid arthritis (RA). Methods We used the National COVID Cohort …

Background The risk of SARS-CoV-2 infection and severity with disease modifying therapies
(DMTs) in multiple sclerosis (MS) remains unclear, with some studies demonstrating …

Objective To estimate risks for all‐cause mortality and for severe COVID‐19 in multiple
sclerosis patients and across relapsing–remitting multiple sclerosis patients exposed to …

The SARS-CoV-2 pandemic has raised particular concern for people with Multiple Sclerosis,
as these people are believed to be at increased risk of infection, especially those being …

Background Outcomes of COVID-19 in PwMS (persons with Multiple Sclerosis) on
immunosuppressive therapies, particularly B-cell depletors, can be unpredictable. There has …

Background At this time vaccination against SARS-CoV2 is a global priority. Cases with
multiple sclerosis (MS) were among the first vaccinated populations in Iran. We evaluated …

Background Rituximab is extensively used for multiple sclerosis (MS) treatment. However,
the best dosage remains to be established. It has been proposed that retreatment could be …

Multiple sclerosis (MS) most commonly presents in young adults, although 3–5% of patients
develop MS prior to the age of 18 years. The new and comprehensive consensus for the …